Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials
AuthorUnger, Joseph M
Moseley, Anna B
Cheung, Christabel K
Osarogiagbon, Raymond U
Ramsey, Scott D
Hershman, Dawn L
JournalJournal of clinical oncology
PublisherAmerican Society of Clinical Oncology
MetadataShow full item record
AbstractPURPOSE: Patients with cancer living in socioeconomically disadvantaged areas have worse cancer outcomes. The association between socioeconomic deprivation and outcomes among patients with cancer participating in clinical trials has not been systematically examined. METHODS: We examined survival outcomes for patients enrolled in phase III and large phase II clinical trials for major cancers conducted by the SWOG Cancer Research Network from 1985 to 2012. Socioeconomic deprivation was measured using trial participants' residential zip codes linked to the Area Deprivation Index (ADI). Five-year overall survival, progression-free survival, and cancer-specific survival were examined using Cox regression frailty models, adjusting for age, sex, and race, and separately for insurance status, prognostic risk, and rural or urban residency. RESULTS: We examined 41,109 patients from 55 trials comprising 24 cancer histology and stage-specific cohorts. Compared with trial participants in the most affluent areas (ADI, 0%-20%), trial participants from areas with the highest socioeconomic deprivation (ADI, 80%-100%) had worse overall (hazard ratio [HR] = 1.28, 95% CI, 1.20 to 1.37, P < .001), progression-free (HR = 1.20, 95% CI, 1.13 to 1.28, P < .001), and cancer-specific survival (HR = 1.27, 95% CI, 1.18 to 1.37, P < .001). The results were similar after adjusting for insurance status, prognostic risk, and rural or urban residency. There was a continuous increase in risk of all outcomes as the ADI quintile increased. CONCLUSION: In patients with cancer with access to protocol-directed care in clinical trials, high area-level socioeconomic deprivation was associated with worse survival. Future research should examine whether the etiology of this residual disparity is related to reduced access to supportive care or postprotocol therapy and/or to differences in health status not reflected by protocol selection criteria.
Clinical Trials as Topic
Health Status Disparities
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15615
- Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials.
- Authors: Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL
- Issue date: 2018 Aug 3
- Impact of Socioeconomic Status on Outcomes After Ventricular Assist Device Implantation Using the Area Deprivation Index.
- Authors: Han JJ, Iyengar A, Fowler C, Acker A, Patrick W, Helmers M, Kelly J, Ameer A, Birati EY, Atluri P
- Issue date: 2021 May
- Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials.
- Authors: Chavez-MacGregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL
- Issue date: 2018 Apr 15
- Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings.
- Authors: Unger JM, Blanke CD, LeBlanc M, Barlow WE, Vaidya R, Ramsey SD, Hershman DL
- Issue date: 2020 Apr 1
- Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
- Authors: Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL
- Issue date: 2009 Jul 15